Posted by Michael Wonder on 18 Feb 2018
GSK receives European approval for expanded indication for Fluarix Tetra (influenza vaccine) for ages six months and older
15 February 2018 - GSK today announced the expanded indication for Fluarix Tetra (quadrivalent influenza vaccine) has been approved in Europe to include adults and now children from six months of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.
Fluarix Tetra has also been approved to be concomitantly administered with pneumococcal polysaccharide vaccines in people aged 50 years and above.
Prior to this, the vaccine was approved for active immunisation against influenza A subtype viruses and type B viruses, in people three years of age and older.
